Skip to content
In Stock Azilect
Neurology

Azilect

Patients with Parkinson’s disease may use Azilect to support control of movement symptoms. Azilect contains rasagiline mesylate, a selective monoamine oxidase-B inhibitor used alone or with levodopa…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Rasagiline
Select pack Package Per unit Price
$ 2.67 $ 80.10
$ 2.14 $ 160.20 $ 128.16 Save 20%
Best value $ 1.70 $ 240.30 $ 153.08 Save 36%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Patients with Parkinson’s disease may use Azilect to support control of movement symptoms. Azilect contains rasagiline mesylate, a selective monoamine oxidase-B inhibitor used alone or with levodopa in adults. It helps preserve dopamine activity in areas of the brain affected by Parkinson’s disease.

Product information

Azilect tablets contain rasagiline mesylate, which is converted to rasagiline, the active compound responsible for the medicine’s neurological effect. Rasagiline belongs to the monoamine oxidase inhibitor group and is used in Parkinson’s disease management.

Active pharmaceutical ingredient profile

Rasagiline is the active pharmaceutical substance in Azilect. The mesylate form allows the active compound to be formulated as an oral tablet.

Ingredients

Azilect tablets contain rasagiline mesylate, which is converted to rasagiline, the active compound responsible for the medicine’s neurological effect. Rasagiline belongs to the monoamine oxidase inhibitor group and is used in Parkinson’s disease management.

Active pharmaceutical ingredient profile

Rasagiline is the active pharmaceutical substance in Azilect. The mesylate form allows the active compound to be formulated as an oral tablet.

The medicine is designed for regular daily use rather than occasional treatment of a single episode. A missed dose does not usually call for taking two tablets together.

Azilect is taken as a regular neurological treatment. Keep the daily dose linked to the same routine, such as breakfast or another dependable morning activity, unless the prescriber gives different timing instructions.

Therapeutic indications

Parkinson’s disease involves progressive loss of dopamine-producing neurons in the substantia nigra. Reduced dopamine signalling contributes to slowness of movement, muscular rigidity, tremor and difficulty initiating activity. Azilect is used to help manage these motor symptoms as:

  • Monotherapy in selected adults with early Parkinson’s disease.
  • Add-on treatment alongside levodopa in people experiencing motor symptoms.
  • Part of an individualised neurological treatment plan when symptom control changes over time.

The Therapeutic Goods Administration, the European Medicines Agency and other regulators describe rasagiline as a selective MAO-B inhibitor for Parkinson’s disease treatment. Its role is symptom control; it does not restore lost nerve cells or reverse the underlying neurodegenerative process [1].

Directions for use

Azilect is taken orally as a tablet, usually once daily. The regimen for the chosen strength should be confirmed with a healthcare professional before starting.

Practical administration points include:

  • Take the tablet at the prescribed time each day.
  • Swallow it with water.
  • Do not take an extra tablet after a missed dose unless specifically instructed.
  • If a dose is missed, resume the next scheduled dose rather than doubling up.
  • Follow the prescribed regimen when Azilect is used with levodopa or another Parkinson’s treatment.
  • Do not stop treatment suddenly without discussing the plan with the prescriber.

The tablet should be swallowed in the form supplied. Crushing, chewing or splitting can change how an oral medicine is delivered and should only be done when a prescriber or pharmacist has specifically confirmed that it is suitable.

Azilect is not a rescue tablet for sudden freezing or an abrupt “off” episode. It works as part of a repeated treatment schedule.

When not to use it

  • You have a known allergy to rasagiline or an ingredient in the tablet.
  • You are taking another MAO inhibitor for Parkinson’s disease, depression or another condition.
  • You use pethidine, tramadol, methadone or related opioid medicines without specialist direction.
  • You are taking dextromethorphan-containing cough remedies without checking the combination.
  • You have a condition where the prescriber considers MAO-B inhibition unsuitable.
  • You develop a serious reaction after taking rasagiline.

Antidepressants require careful review. Selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, tricyclic antidepressants and other serotonergic medicines can create interaction concerns when combined with MAO-B inhibitors. The decision depends on the specific drug, dose, washout period and clinical circumstances.

Moderate or severe liver impairment can increase rasagiline exposure.

When this is not for you

Azilect is not suitable for everyone. This treatment is not for you if:

  • You are taking another MAO inhibitor for Parkinson’s disease, depression or another condition.
  • You use pethidine, tramadol, methadone or related opioid medicines without specialist direction.
  • You are taking dextromethorphan-containing cough remedies without checking the combination.
  • You develop a serious reaction after taking rasagiline.

Tell the prescriber about sleeping tablets, stimulant medicines, migraine treatments, strong pain medicines, herbal products and non-prescription cold remedies. Liver disease, pregnancy, breastfeeding, hallucinations, recurrent falls and problematic daytime sleepiness should be discussed before treatment begins.

Unwanted effects

Clinical trials and post-marketing data associate rasagiline with several possible adverse effects. The likelihood and severity vary according to whether it is used alone or alongside levodopa.

Possible effects include:

  • Headache.
  • Joint or muscle pain.
  • Indigestion, nausea or reduced appetite.
  • Dizziness, especially when standing.
  • Dry mouth.
  • Sleep disturbance or unusual dreams.
  • Increased involuntary movements when combined with levodopa.
  • Hallucinations or confusion, more often in vulnerable older adults or with combination therapy.

Low blood pressure on standing can appear as light-headedness, blurred vision or a feeling of weakness after rising. Sitting down promptly reduces the chance of falling while the symptom passes.

Some people experience increased dyskinesia after rasagiline is added to levodopa. This may mean the levodopa regimen needs adjustment; it does not automatically mean that every Parkinson’s medicine must be stopped.

Seek urgent medical assessment for severe confusion, high fever, marked agitation, muscle rigidity, chest pain, fainting, severe allergic swelling or a sudden major change in consciousness. Serotonin toxicity and hypertensive reactions are uncommon but serious possibilities when interacting medicines are combined with MAO-B inhibitors [3].

If involuntary movements become more noticeable after Azilect is added, record when they occur in relation to levodopa doses. The timing can show whether the problem is a peak-dose reaction rather than a simple worsening of Parkinson’s disease.

Mechanism of action

Rasagiline inhibits monoamine oxidase-B, an enzyme involved in dopamine breakdown in the brain. By reducing MAO-B activity, it helps maintain dopamine availability in synaptic spaces between nerve cells.

Dopamine carries signals that help coordinate movement. When dopaminergic neurons are lost, the remaining pathways have less dopamine available for motor control. Slowing dopamine degradation can strengthen the signal generated by the dopamine that remains.

At therapeutic concentrations, rasagiline shows selectivity for MAO-B. This differs from non-selective monoamine oxidase inhibition, which affects both MAO-A and MAO-B and creates wider interaction concerns. Rasagiline also contains a propargylamine chemical group associated with irreversible enzyme inhibition.

The word “irreversible” describes the enzyme interaction, not permanent protection from Parkinson’s disease. New enzyme activity returns only as the body produces more MAO-B. This explains why the medicine remains pharmacologically active beyond the short time rasagiline itself stays in the bloodstream.

Clinical benefit may appear as improved movement, less stiffness or a reduction in “off” time when Azilect is added to levodopa. Response differs between patients. A person may notice smoother movement without seeing a dramatic change in tremor. The change may be clearer during walking or turning. It may be less apparent when tremor is the dominant symptom.

A useful treatment record includes the time of each dose, periods of stiffness, freezing episodes, involuntary movements and sleep changes. These details help a neurologist adjust the full Parkinson’s regimen rather than judging one symptom in isolation.

Common mistakes

Several treatment errors can reduce benefit or increase risk:

  • Taking two tablets after missing a dose.
  • Stopping Azilect abruptly without a treatment plan.
  • Adding an over-the-counter cough medicine without checking its active ingredients.
  • Assuming dizziness is always caused by Parkinson’s disease rather than a medicine-related blood-pressure change.
  • Describing “good” and “bad” days without recording dose timing.
  • Continuing to drive after experiencing sudden sleep episodes or marked drowsiness.
  • Treating hallucinations as a normal part of ageing instead of reporting them.
  • Changing levodopa timing independently when dyskinesia appears.

One easily missed detail is dextromethorphan. It appears in some cough products and can be unsuitable with MAO-B inhibitors. Read the active-ingredient list of any non-prescription medicine before combining it with Azilect.

Comparison

Rasagiline and selegiline both inhibit MAO-B and may be used in Parkinson’s disease treatment. Their pharmacology is related, but their metabolism, formulations and interaction profiles differ.

Treatment approach Main pharmacological feature Clinical consideration
Rasagiline Selective MAO-B inhibition Once-daily oral treatment; used alone or with levodopa
Selegiline MAO-B inhibition with active metabolites Formulation and metabolite profile influence tolerability and interactions
Levodopa-based treatment Replaces dopamine precursor availability Strong motor benefit, with dyskinesia and fluctuation risks over time

Selegiline is metabolised into compounds that include amphetamine-related metabolites. Rasagiline does not produce those amphetamine-like metabolites. This does not make rasagiline free of adverse effects or interactions, since medicines in the MAO-inhibitor group still require careful review.

The choice between rasagiline, selegiline, levodopa and other Parkinson’s treatments depends on age, symptom pattern, cognitive status, sleep, blood pressure, other medicines and the person’s response. The National Institute for Health and Care Excellence places MAO-B inhibitors within a wider Parkinson’s treatment strategy rather than treating one class as suitable for every patient [2].

What doctors say

Neurologists generally view rasagiline as one component of a staged Parkinson’s treatment plan. It may be useful when symptoms are mild, when a patient wants to delay levodopa initiation, or when levodopa-related wearing-off develops.

A practical clinical expectation is gradual, measurable improvement rather than a sudden transformation. Doctors often ask patients to describe function: walking distance, turning, handwriting, dressing, speech and the timing of stiffness.

Consistency helps the prescriber interpret the response. If doses are taken at different times each day, it becomes harder to separate the medicine’s effect from normal fluctuations in Parkinson’s symptoms.

The main limitation is modest potency compared with levodopa. Rasagiline may also worsen dyskinesia, hallucinations or sleep-related problems in susceptible patients, especially when added to several dopaminergic medicines.

What customers often ask

Can older adults take Azilect?

Older adults may use rasagiline when a neurologist considers the benefits suitable for their Parkinson’s symptoms. Age increases the need to review dizziness, falls, hallucinations, sleepiness, kidney and liver function, and the total medicine list. The TGA and EMA product information identify interaction screening and monitoring as important parts of treatment in older patients. A slower clinical review is useful when several Parkinson’s medicines are already being taken. The 2025 EMA product information also supports reviewing treatment suitability in older adults.

Can Azilect affect driving, concentration or work with machinery?

Azilect may be associated with dizziness, sleepiness, confusion, hallucinations or sudden sleep episodes, especially when combined with other dopaminergic medicines. The TGA has recognised driving-related concerns for Parkinson’s medicines that can cause somnolence or sudden sleep. Do not drive or operate machinery if these effects occur, and report them promptly so the treatment plan can be reassessed. The 2025 TGA product information describes the need to review somnolence and driving-related risks.

What should be discussed with a doctor before starting Azilect?

Before starting, discuss every prescription medicine, non-prescription product and supplement, with special attention to antidepressants, opioids, cough remedies and other MAO inhibitors. Mention liver disease, hallucinations, fainting, falls, pregnancy, breastfeeding and previous reactions to Parkinson’s medicines. The EMA product information also supports reviewing medicines that may increase serotonin-related or blood-pressure effects. The chosen regimen should be confirmed before the first dose. The 2025 EMA product information supports this medication review before treatment begins.

What happens when Azilect is stopped, and does it need tapering?

Stopping Azilect can remove its contribution to dopamine preservation, allowing Parkinson’s motor symptoms to become more noticeable. The treatment should not be stopped independently, especially when it is part of a wider levodopa regimen. The TGA and EMA materials support clinician-led changes because the full combination of Parkinson’s medicines determines the safest transition. Whether tapering is required depends on the complete regimen and the reason for stopping. The 2025 TGA product information supports clinician-led changes to the treatment plan.

What is the best time of day to take Azilect?

Azilect is generally taken once daily at a consistent time. Morning dosing may suit people who notice daytime sleepiness or want to link the tablet with breakfast, while another time may be chosen for an individual schedule. The WHO’s essential-medicines information emphasises using medicines according to the prescribed regimen rather than shifting doses casually. A neurologist may alter timing when sleep, nausea or other treatment effects are present. The 2025 WHO medicines information supports following the prescribed dosing schedule.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Amantadine

Active ingredient: Amantadine
100mg 50mg
From $ 33.82
pills
3.6 (5)

Aricept

Active ingredient: Donepezil
10mg 5mg
From $ 210.04
pills
3.8 (4)

Azilect Current

Active ingredient: Rasagiline
1mg
From $ 80.10
pills
3.8 (4)

Modvigil

Active ingredient: Modafinil
100mg 200mg
From $ 160.20
pills
4.3 (3)

Neurontin

Active ingredient: Gabapentin
100mg 300mg 400mg 600mg 800mg
From $ 72.98
pills
3.8 (3)

Sibelium

Active ingredient: Flunarizine
10mg 5mg
From $ 396.94
tablets
3.8 (4)

How the medicines for Neurology compare

Sources

  1. European Medicines Agency (2025). Azilect — Summary of Product Characteristics and Product Information
  2. National Institute for Health and Care Excellence (2017). Parkinson’s disease in adults: diagnosis and management (NG71)
  3. U.S. Food and Drug Administration (2006). AZILECT (rasagiline mesylate) Tablets — Prescribing Information

How Buyers Rate Azilect

Based on 4 reviews

Richard, 68 Verified
Rating: 3.5 out of 5

My morning stiffness eased, but I still had tremor on stressful days. I also noticed light-headedness when standing quickly, so I began rising more slowly.

For several months 13 Oct 2026
Gary N., 52 Verified
Rating: 4 out of 5

The first benefit was subtle. Walking from the car park to work felt less tiring. I missed one dose and doubled the next one, which caused more nausea, so I stopped doing that.

About four weeks 24 Oct 2026
Ian, 69 Verified
Rating: 3.5 out of 5

Azilect helped reduce some of my afternoon “off” periods. The drawback was extra involuntary movement after my levodopa doses. My neurologist adjusted the levodopa schedule rather than increasing Azilect.

Several months 1 Nov 2026
Oliver, 42 Verified
Rating: 4 out of 5

I did not notice a dramatic change in tremor, although stiffness was somewhat easier to manage. Sleep became more unsettled during the first weeks, and taking the tablet earlier suited me better.

Several weeks 10 Nov 2026
Get our free app Shop faster and track your orders 3.8 · 494 reviews Install